Navigation Links
Precision Therapeutics President and CEO Sean McDonald Recognized as Pittsburgh Technology Council Tech 50 CEO of the Year
Date:10/15/2010

PITTSBURGH, Oct. 15 /PRNewswire/ -- Precision Therapeutics announced today that its President and Chief Executive Officer Sean McDonald was recognized as CEO of the Year by the Pittsburgh Technology Council.

(Photo: http://photos.prnewswire.com/prnh/20101015/NE83126 )

(Photo: http://www.newscom.com/cgi-bin/prnh/20101015/NE83126 )

The Tech 50 award recognizes the accomplishments of 50 of southwestern Pennsylvania's most successful entrepreneurs whose innovation and creativity have been used to strategically enhance the ideals and growth of their organization as well as the community and greater region. McDonald was selected by an independent panel of technology experts and the category awards were presented on October 14, 2010, at the Hilton Downtown Pittsburgh.

Sean joined Precision in 2001 and has since dedicated his career to developing innovative technologies with the goal of helping physicians to select customized treatment to meet the individual needs of each cancer patient. He most recently led Precision to earn a first place ranking as an industry leader in the health care division in the Pittsburgh region.  Because of Sean's passion, leadership and vision, Precision Therapeutics remains at the forefront of personalized diagnostics and research for individualized cancer therapy, with nearly 32,000 patient specimens sent for ChemoFx® testing and 18 active clinical trials.

About Precision Therapeutics

Precision Therapeutics, a life-science company based in Pittsburgh, Pennsylvania, is committed to improving outcomes of cancer patients. As leaders in the science of individualizing cancer therapy through the use of a proprietary and unique live-tissue platform, Precision develops novel markers to help guide treatment decisions based on the biological processes of each individual's cancer.

Precision's state of the art bioinformatics combined with the analysis of the live molecular, proteomic and genomic activity of each patient's cancer offer an innovative foundation for further development and commercialization of novel predictive markers for cancer therapy.  Precision's first commercial test, ChemoFx®, is a proprietary drug response marker which measures an individual's malignant tumor response to a range of standard therapeutic alternatives under consideration by a physician.

For more information, please visit www.chemofx.com.


'/>"/>
SOURCE Precision Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Applied Precision Installs New DeltaVision
2. OMX® Super-Resolution Imaging System in the Light Microscopy Imaging Center at Indiana University
3. Pinpoint precision: Delivering a biochemical payload to 1 cell
4. Precision Therapeutics Growing Rapidly as it Augments Research and Development Efforts
5. Stretching single molecules allows precision studies of interacting electrons
6. Precision Antibody Wins Contract to Develop Gold Standard Antibodies as Part of National Cancer Institutes Clinical Proteomics Technologies for Cancer (CPTC) Initiative
7. Precision Therapeutics Named to Inc. Magazines List of Fastest Growing Companies
8. New statistical technique improves precision of nanotechnology data
9. Precision Stability Storage Announces Upcoming Expansion
10. NISTs LIDAR may offer peerless precision in remote measurements
11. Frost & Sullivan Awards Precision Biosciences for Technology Innovation and Molecular Design Process in the Genomics Market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/22/2017)... Ca (PRWEB) , ... June 22, 2017 , ... The ... It took 20 years until the first data on cross-contamination of human cell lines ... has been an increasing issue in cell culture labs and is associated with dramatic ...
(Date:6/22/2017)... ... 22, 2017 , ... Charm Sciences, Inc. is pleased to announce that its ... be appropriate as a screening test at dairies and farms for raw commingled cow ... the Charm EZ Lite system. These systems are a combination incubator and reader in ...
(Date:6/20/2017)... Fort Lauderdale, Florida (PRWEB) , ... June 20, 2017 , ... ... and commitment in men. While researching her latest book, Men Chase, Women Choose: The ... that showed that love has a physiological effect on men. ”The logical next step, ...
(Date:6/20/2017)... , June 20, 2017  Kibow Biotech Inc., a ... announce the issuance of a new patent covering a ... by the U.S. Patent and Trademark Office on May ... of the Buzz of Bio award in 2014 in ... to developing non-drug approaches to chronic disease. Renadyl™, the ...
Breaking Biology Technology:
(Date:3/23/2017)... Research and Markets has announced the addition of the "Global ... 2025" report to their offering. ... The Global Vehicle Anti-Theft System Market is ... next decade to reach approximately $14.21 billion by 2025. ... all the given segments on global as well as regional levels ...
(Date:3/22/2017)... , March 21, 2017 Vigilant ... company serving law enforcement agencies, announced today the appointment ... as director of public safety business development. ... law enforcement experience, including a focus on the aviation ... his most recent position, Mr. Sheridan served as the ...
(Date:3/16/2017)... 2017 CeBIT 2017 - Against identity fraud with DERMALOG solutions "Made ... ... Used combined in one project, multi-biometric solutions provide a crucial contribution against identity ... Used combined in one project, multi-biometric ... ...
Breaking Biology News(10 mins):